Home > News > Introgen applies to market Advexin in Europe
November 13th, 2007
Introgen applies to market Advexin in Europe
Introgen Therapeutics Inc. and its subsidiary, Gendux Molecular Ltd., have submitted a marketing authorization application to the European Medicines Agency for Advexin, a tumor suppressor therapy for use in the treatment of a type of cancer known as Li-Fraumeni Syndrome.
Austin-based Introgen (NASDAQ: INGN) has offices housing a clinical and regulatory development staff of about 70 in the Texas Medical Center plus a manufacturing facility nearby.
A year ago, the biotech company obtained an exclusive worldwide license to a portfolio of patents from The University of Texas M.D. Anderson Cancer Center, along with agreements to commercialize products based on the licensed technologies. Those patents are focused on the delivery of biologically active proteins, polypeptides and peptides on the nanoparticle level.
Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014
Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014
Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014
Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014
High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014
Guo Lab Shows Potential of RNA as Heat-resistant Polymer Material for Nanoarchitectures April 23rd, 2014
Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014
National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014